Fluicell - Public Comps and Valuation Multiples

Fluicell Overview

About Fluicell

Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.

Founded

2012

HQ

Employees

Website

fluicell.com

Sectors

Drug Development & Therapeutics
Biopharmaceuticals
BioTech

Financials

Last FY Revenue $0.2M

Last FY EBITDA -$1.6M

EV

-$0.9M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Fluicell Financials

See Fluicell valuation multiples based on analyst estimates

Fluicell P&L

In the most recent fiscal year, Fluicell reported revenue of $0.2M and EBITDA of -$1.6M.

Fluicell expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Fluicell valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$0.2M	XXX	XXX	XXX
Gross Profit	XXX	$0.4M	XXX	XXX	XXX
Gross Margin	XXX	202%	XXX	XXX	XXX
EBITDA	XXX	-$1.6M	XXX	XXX	XXX
EBITDA Margin	XXX	-806%	XXX	XXX	XXX
EBIT	XXX	-$1.7M	XXX	XXX	XXX
EBIT Margin	XXX	-852%	XXX	XXX	XXX
Net Profit	XXX	-$1.6M	XXX	XXX	XXX
Net Margin	XXX	-834%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Fluicell including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Fluicell achieved $0.2M in revenue and -$1.6M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$0.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$0.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	202.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	-$1.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	-806.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	-$1.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	-852.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	-$1.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	-834.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Fluicell

This financial data table provides comprehensive performance metrics for Fluicell, a company based in Sweden. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Fluicell reported $0.2M in total revenue.
Fiscal year EBITDA was -$1.6M.
The company maintained a gross profit margin of 202.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was -806.5%.
Net profit margin reached -834.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Fluicell. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Fluicell Stock Performance

Fluicell has current market cap of SEK 13.1M (or $1.4M), and EV of -SEK 8.6M (or -$0.9M).

Market Cap Evolution

Fluicell Stock Data

As of December 3, 2025, Fluicell's stock price is SEK 9 (or $1).

See Fluicell trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
-$0.9M	$1.4M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Fluicell Valuation Multiples

Fluicell's trades at -4.6x EV/Revenue multiple, and 0.6x EV/EBITDA.

See valuation multiples for Fluicell and 15K+ public comps

Fluicell Financial Valuation Multiples

As of December 3, 2025, Fluicell has market cap of $1.4M and EV of -$0.9M.

Equity research analysts estimate Fluicell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Fluicell's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.4M	XXX	$1.4M	XXX	XXX	XXX
EV (current)	-$0.9M	XXX	-$0.9M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	-4.6x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	0.6x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	0.5x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	-0.8x	XXX	XXX	XXX
EV/FCF	n/a	XXX	0.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Fluicell Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Fluicell Margins & Growth Rates

Fluicell's revenue per employee in the last FY averaged $16K, while opex per employee averaged $0.2M for the same period.

Fluicell's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Fluicell's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Fluicell and other 15K+ public comps

Fluicell Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-806%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$16K	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	1054%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial